Target intelligence / Profile preview

Phospholipase A2 group IIA (PLA2G2A)

Target
PLA2G2A
Molecular classification
Enzyme, Hydrolase, Phospholipase
01

Overview

Phospholipase A2 group IIA (PLA2G2A), commonly known as synovial phospholipase A2 or group IIA secretory phospholipase A2 (sPLA2-IIA), is a calcium-dependent secretory enzyme that plays a pivotal role in lipid metabolism, host defense, and the propagation of inflammatory pathways. Originally isolated from the synovial fluid of rheumatoid arthritis patients, PLA2G2A catalyzes the hydrolysis of the sn-2 ester bond of glycerophospholipids, releasing free fatty acids (such as arachidonic acid) and lysophospholipids. These products serve as precursors for the synthesis of potent pro-inflammatory eicosanoids, including prostaglandins and leukotrienes, which drive chronic inflammatory diseases like rheumatoid arthritis, asthma, and cardiovascular disorders. Beyond its catalytic activity, PLA2G2A acts as a ligand for integrins and other cell-surface receptors, triggering intracellular signaling cascades (such as EGFR/ERK pathways) that promote cell proliferation, migration, and tissue remodeling.

In clinical development, PLA2G2A has been targeted by small-molecule active-site inhibitors like varespladib and varespladib methyl, which were evaluated for inflammatory and cardiovascular indications. However, the Phase III VISTA-16 trial for acute coronary syndrome was halted due to a lack of efficacy and an increased risk of myocardial infarction, highlighting the therapeutic challenges and safety concerns of broad sPLA2 inhibition. More recently, novel therapeutic strategies have emerged, such as kesonotide, a cyclic peptide designed to selectively block the non-catalytic, protein-protein interactions of PLA2G2A with vimentin and EGFR, offering a promising approach for treating advanced solid tumors like prostate cancer. Additionally, circulating levels of PLA2G2A serve as valuable biomarkers for monitoring systemic inflammation, cardiovascular risk, and disease prognosis.

Other names
Synovial phospholipase A2Group IIA secretory phospholipase A2Secretory phospholipase A2 group IIANon-pancreatic secretory phospholipase A2Phosphatidylcholine 2-acylhydrolase 2AsPLA2-IIAPLA2G2
02

Mechanism of action

Inhibition of the active site to block phospholipid hydrolysis and eicosanoid precursor release, or selective inhibition of non-catalytic protein-protein interactions (such as with EGFR and vimentin) to block downstream pro-inflammatory and proliferative signaling.

03

Biological functions

Lipid metabolismInflammatory responseImmune responseHost defenseCell proliferationApoptosis
04

Disease associations

InflammationRheumatoid arthritisCardiovascular diseaseAtherosclerosisCancerSepsisPulmonary fibrosisAsthma
05

Safety considerations

Increased risk of myocardial infarction (as seen in the VISTA-16 trial)Impairment of host defense and increased susceptibility to bacterial infections due to loss of bactericidal activityContext-dependent tumor-promoting or tumor-suppressing effects across different tissues (e.g., tumor-suppressive in gastrointestinal cancers but pro-tumorigenic in prostate cancer)
06

Interacting drugs

3 more in the full profile.

07

Biomarkers

Circulating sPLA2-IIA massCirculating sPLA2-IIA activityPLA2G2A gene expressionPLA2G2A protein levelsrs11573156 genetic variant

Beyond the preview

Go deeper on Phospholipase A2 group IIA (PLA2G2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phospholipase A2 group IIA (PLA2G2A).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call